Regenxbio Inc RGNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Regenxbio Shares Rise on $100 Million Milestone Payment After First Patient Dosed in Eye-Disease Trial
-
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
-
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
-
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
-
Regenxbio Shares Up on WSJ Report of FDA U-Turn on Company's Gene Therapy
-
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
-
REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
-
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Trading Information
- Previous Close Price
- $15.65
- Day Range
- $13.42–15.65
- 52-Week Range
- $5.46–16.19
- Bid/Ask
- $13.93 / $14.20
- Shares Outstanding
- 51.70M
- Market Cap
- $721.18M
- Volume/Avg
- 3M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.87
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 371
- Website
- https://www.regenxbio.com
Valuation
|
Metric
|
RGNX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 36.77 |
Price/Sales | 8.87 |
Price/Cash Flow | — |
Price/Earnings
RGNX
Financial Strength
|
Metric
|
RGNX
|
|---|---|
Quick Ratio | 2.27 |
Current Ratio | 2.62 |
Interest Coverage | −5.43 |
Quick Ratio
RGNX
Profitability
|
Metric
|
RGNX
|
|---|---|
Return on Assets (Normalized) | −53.38% |
Return on Equity (Normalized) | −165.15% |
Return on Invested Capital (Normalized) | −91.29% |
Return on Assets
RGNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|mVxCx% | LOCK|V#y>^ | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|R$^@mD | LOCK|D#QF | $70B | |||
| argenx SE ADR
ARGX
| LOCK|$n$%Y@ | LOCK|P@m | $57B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|llcv!f | LOCK|tDm>w | $42B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|D<<<^< | LOCK|@J@ | $35B | |||
| Moderna Inc
MRNA
| LOCK|whP<Vg | LOCK|hY | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|N?@j$D! | LOCK|#J@< | $26B | |||
| Incyte Corp
INCY
| LOCK|t$TT?B | LOCK|>b | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|@^dVcY< | LOCK|!Fp | $24B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|m>Ch?D | LOCK|wm | $18B |
United States